05B4 Ertel, Adam - Thomas Jefferson University - Thomas Jefferson University
ame004

Adam Ertel, PhD

Contact Dr. Ertel

Kimmel Cancer Center
233 S. Tenth Street, Suite 1009
Philadelphia, PA 19107

(215) 503-7452
(215) 503-9142 fax

Most Recent Peer-reviewed Publications

  1. Retinoblastoma protein potentiates the innate immune response in hepatocytes: Significance for hepatocellular carcinoma
  2. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer
  3. Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation
  4. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint
  5. Functional significance of macrophage-derived exosomes in inflammation and pain
  6. Cyclin D1 induction of dicer governs microRNA processing and expression in breast cancer
  7. Cancer cell proliferation through cyclin D1
  8. Global profiling of prolactin-modulated transcripts in breast cancer in vivo
  9. STAT5A/B gene locus undergoes amplification during human prostate cancer progression
  10. Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer
  11. Dachshund binds p53 to block the growth of lung adenocarcinoma cells
  12. Aberrant BAF57 signaling facilitates prometastatic phenotypes
  13. Erratum: ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice (J Clin Invest. (2013) 123:5 (2332) 10.1172/JCI70042)
  14. Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3
  15. The complex transcriptional landscape of the anucleate human platelet
  16. Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures
  17. Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes
  18. Regulation of miR106b cluster through the RB pathway: Mechanismand functional targets
  19. Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes
  20. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer
0